ProCE Banner Activity

Pooled Data From BREEZE-AD1 and BREEZE-AD2 Examining the Efficacy and Safety of Baricitinib in Patients With Atopic Dermatitis and Atopic Comorbidities

Slideset Download
Conference Coverage
Clinically significant improvements observed in skin symptoms, itch, and sleep disturbance with baricitinib in adults with moderate to severe AD with comorbid atopic conditions.

Released: July 27, 2020

Expiration: July 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.